A Study of 177Lu-FAP-2286 in Advanced Solid Tumors
Solid Tumor
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 222 (planned)
- Started
- Jul 30, 2021
- Main results expected
- Dec 31, 2027
- Fully finished
- Jun 30, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 1: Dose-limiting toxicity (DLTs)
Measured over: From first dose of study drug through at least 6-8 weeks after end of treatment (up to approximately 2 years)
Phase 1: recommended Phase 2 dose (RP2D)
Measured over: From first dose of study drug through at least 6-8 weeks after end of treatment (up to approximately 2 years)
Phase 1: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) of [177Lu]Lu FAP 2286
Measured over: From first dose of study drug through at least 6-8 weeks after end of treatment (up to approximately 2 years)
Phase 2: Objective Response Rate (ORR)
Measured over: From date of first [177Lu]Lu FAP 2286 treatment until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to 59 months
Phase 2: Dose-limiting toxicity (DLTs)
Measured over: Assessed within 4 weeks of first Lu-FAP2286 treatment
Phase 2: recommended Phase 2 dose (RP2D)
Measured over: From first dose of study drug through at least 6-8 weeks after end of treatment (up to approximately 2 years)
Phase 2: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) of [177Lu]Lu FAP 2286
Measured over: From first dose of study drug through at least 6-8 weeks after end of treatment (up to approximately 2 years)
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04939610 · record last updated 2026-07-24 · checked 2026-11-09 15:47 UTC